Wednesday, July 8, 2026

pharma · Cystic Fibrosis (CF) · Accidental Hypothermia · SION

Sionna Therapeutics

Sionna Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker SION. Primary therapeutic focus areas include Cystic Fibrosis (CF), Accidental Hypothermia, Bleeding, End-stage Ki

Boston, USA HQ
2019 Founded
74 Employees
Public company Type
SION · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Founded
2019
Employees
74
Programs
5
Drugs
4
Patents
0
Clinical program

SION-451

Phase 1 · small molecule · Cystic Fibrosis (CF)

SION-451 for Cystic Fibrosis (CF) is a Phase 1 program (small_molecule) at Sionna Therapeutics with 1 ClinicalTrials.gov record(s).

← All Sionna Therapeutics projects Phase 1 small molecule active

Internal code SION-451-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sionna Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Cystic Fibrosis (CF)
Status
active
Trials
1

Clinical trials